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SYSTEMATIC REVIEW AND META-ANALYSIS
Coronary Artery Calcification and Plaque 
Characteristics in People Living With HIV: A 
Systematic Review and Meta- Analysis
Cullen Soares , MD; Amjad Samara, MD; Matthew F. Yuyun , MD, PhD; Justin B. Echouffo- Tcheugui , MD, 
MPhil, PhD; Ahmad Masri , MD, MS; Ahmad Samara, MD; Alan R. Morrison , MD, PhD; Nina Lin , MD; 
Wen- Chih Wu , MD, MPH; Sebhat Erqou , MD, PhD
BACKGROUND: Studies have reported that people living with HIV have higher burden of subclinical cardiovascular disease, but 
the data are not adequately synthesized. We performed meta- analyses of studies of coronary artery calcium and coronary 
plaque in people living with HIV.
METHODS AND RESULTS: We performed systematic search in electronic databases, and data were abstracted in standardized 
forms. Study- specific estimates were pooled using meta- analysis. 43 reports representing 27 unique studies and involving 
10 867 participants (6699 HIV positive, 4168 HIV negative, mean age 52 years, 86% men, 32% Black) were included. The 
HIV- positive participants were younger (mean age 49 versus 57 years) and had lower Framingham Risk Score (mean score 6 
versus 18) compared with the HIV- negative participants. The pooled estimate of percentage with coronary artery calcium >0 
was 45% (95% CI, 43%– 47%) for HIV- positive participants, and 52% (50%– 53%) for HIV- negative participants. This difference 
was no longer significant after adjusting for difference in Framingham Risk Score between the 2 groups. The odds ratio of 
coronary artery calcium progression for HIV- positive versus - negative participants was 1.64 (95% CI, 0.91– 2.37). The pooled 
estimate for prevalence of noncalcified plaque was 49% (95% CI, 47%– 52%) versus 20% (95% CI, 17%– 23%) for HIV- positive 
versus HIV- negative participants, respectively. Odds ratio for noncalcified plaque for HIV- positive versus - negative participants 
was 1.23 (95% CI, 1.08– 1.38). There was significant heterogeneity that was only partially explained by available study- level 
characteristics.
CONCLUSIONS: People living with HIV have higher prevalence of noncalcified coronary plaques and similar prevalence of coro-
nary artery calcium, compared with HIV- negative individuals. Future studies on coronary artery calcium and plaque progres-
sion can further elucidate subclinical atherosclerosis in people living with HIV.
Key Words: calcium score ■ cardiovascular disease ■ coronary artery calcium ■ coronary plaque ■ human immunodeficiency virus ■ 
subclinical atherosclerosis
Patients with HIV infection are living longer be-cause of effective antiretroviral therapy (ART). Consequently, these patients are experiencing 
an increasing burden of cardiovascular disease (CVD). 
The focus of care is thus shifting to primary CVD pre-
vention once patients are stable on their ART regimen.1 
In addition to traditional CVD risk factors, people living 
with HIV (PLHIV) are predisposed to CVD attributable 
to HIV- specific factors, including chronic HIV infection, 
low- grade inflammation, and cardiometabolic effects 
of ART.2 Coronary computed tomography (CT) has 
increasingly been used to guide treatment strategies 
in the general population for primary prevention and 
has also been used for patients with HIV.3,4 Because 
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traditional risk factor calculators may not adequately 
capture the full extent of the CVD risk in this population, 
CT imaging markers such as coronary artery calcium 
(CAC) may be useful to fill in this gap for risk assess-
ment.5 Prior studies have suggested that patients with 
HIV have a higher burden of subclinical atherosclerosis, 
including carotid stenosis and accelerated coronary 
aging based on CAC score measures.6– 8 Additionally, 
asymptomatic patients with HIV have been reported 
to have higher rates of noncalcified plaques in some 
studies,6 which are considered higher risk for rupture 
leading to cardiac events. However, studies have not 
found a consistent association between HIV and CAC 
burden, and prior reviews have not adequately synthe-
sized the data on CAC and coronary plaque burden 
in PLHIV.8 Given inconclusive data from prior studies 
and reviews, and the rapid expansion of the literature 
on HIV risk for CAC, we aimed to perform a systematic 
review and meta- analysis of all the available evidence 
on CAC and coronary plaque burden in PLHIV and 
compare with HIV- negative individuals to elucidate any 
differences in subclinical atherosclerotic burden.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
Search Strategy
We searched the PubMed and EMBASE databases 
from inception until September 2020 for English- 
language articles on coronary artery calcium (CAC) 
score and CVD in patients with HIV. PubMed search 
used the following key search terms related to HIV, 
CVD, and CAC: Human Immunodeficiency Virus, 
HIV, AIDS, Acquired Immune Deficiency Syndrome, 
Cardiovascular Disease, Coronary Artery Disease, 
Coronary Artery Calcium and Agatston Score. We 
also scanned reference lists of relevant articles. We 
used the following inclusion criteria to select studies: 
(1) observational study (cross- sectional or longitudinal 
design); (2) study of patients with HIV (with or without 
HIV- negative controls), (3) study on adults >18 years of 
age, (4) reported data on CAC score (measured using 
noncontrast cardiac CT) or coronary plaque (meas-
ured using coronary CT angiography).
Data Extraction
We extracted prespecified information in duplicate from 
the publications using standardized forms (performed 
by C.S., Ah.S., and Am.S.). Relevant study- level infor-
mation including study location, study year, design, 
size, average age of participants (mean or median, 
whichever was the available summary measure of the 
age of participants), proportion of men, average values 
of blood pressure, proportion of smokers, proportion 
with diabetes mellitus, and average Framingham Risk 
Score (FRS) values were extracted for HIV- positive 
cases and HIV- negative controls separately and com-
bined, wherever available. The average duration of 
HIV Infection, proportion on ART, average duration on 
ART, and average CD4 count were extracted for the 
HIV- positive participants. Information on measurement 
method and results of the following subclinical ath-
erosclerosis measures was recorded for HIV- positive 
CLINICAL PERSPECTIVE
What Is New?
• Although several studies on coronary artery 
calcium and coronary plaque burden in people 
living with HIV have been published in recent 
years, the data have not been adequately syn-
thesized, and their relevance to cardiovascular 
risk stratification in this group is not clear.
• This meta- analysis found that people living with 
HIV have similar burden of coronary calcium 
and total coronary plaque and higher burden 
of noncalcified coronary plaque, compared to 
HIV- negative controls.
• The findings suggest that a more vulnerable 
form of subclinical atherosclerosis may develop 
earlier in people with HIV.
What Are the Clinical Implications?
• The findings in this meta- analysis have impli-
cations on cardiovascular disease screening 
considerations for patients with HIV (especially 
those with risk factors for cardiovascular dis-
ease) at a younger age.
• Primary care providers or preventative cardi-
ologists may consider a lower threshold to use 
coronary calcium scoring to help risk stratify 
their patients with HIV; coronary computed to-
mographic angiography can also be considered 
to identify noncalcified coronary plaque in these 
patients.
• Future randomized clinical trials will help to 
determine definitively the utility of noninvasive 
markers such as coronary calcium scoring and 
computed tomographic angiography in pre-
venting cardiovascular disease in this group.
Nonstandard Abbreviations and Acronyms
FRS Framingham Risk Score
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cases and (where available) HIV- negative controls: (1) 
Average CAC Agatston score (mean or median) with 
measure of dispersion (SD or interquartile range), (2) 
percentage with CAC >0, (3) percentage with CAC 
>100, (4) percentage with CAC progression, (5) per-
centage with coronary plaque, (6) percentage with 
noncalcified coronary plaque, and (7) percentage with 
calcified coronary plaque. Information on CAC pro-
gression definition for studies reporting these data are 
as follows: significant increase from baseline (>2.5 on 
square root scale) with median follow- up of 19 months9; 
new CAC with median follow- up of 5 years10; new CAC 
>0 or >10- unit change per year or >10% change per 
year with follow- up over 6 years11; new CAC with mean 
follow- up of 2.4  years12; new CAC or significant in-
crease from baseline (>2.5 on square root scale) with 
follow- up over 2  years13; and new CAC with median 
follow- up of 2.2 years (HIV- positive) and 3.4 years (HIV- 
negative) 14; CAC percentage increase >15% per year 
with follow- up of 0.5 to 3  years15; new CAC or per-
centage increase >15% per year with median follow- up 
of 1.2 years.16 For studies comparing HIV- positive and 
HIV- negative individuals directly, measures of relative 
risk (ie, odds ratios) were also extracted for each of the 
preceding measures, where available. Discrepancies 
were resolved by consensus, adjudicated by a fourth 
reviewer (S.E.).
Statistical Analysis
Only a subset of the studies included both HIV- positive 
participants and HIV- negative controls. To ensure that 
our conclusions on comparisons by HIV status are 
valid, we present findings of analyses restricting to 
studies that recruited both HIV- positive and  negative 
participants in parallel with results of overall analyses 
as appropriate. We calculated the weighted mean of 
study- level characteristics such as average age, per-
centage male, percentage Black, percentage smok-
ers, percentage with hypertension, average blood 
pressure, average CD4 count, and so on, weighted by 
the appropriate denominators (N). Where appropriate, 
the P value comparing summary study- level character-
istics between HIV- positive and HIV- negative partici-
pants was calculated from a linear regression model 
of each variable upon HIV status, analytically weighted 
by N for each study (ie, fixed- effects meta- regression). 
Standard errors for the study- specific prevalence es-
timates were determined from the point estimate and 
the sample size (N) assuming a binomial distribution. 
For studies with data on average CAC score, we in-
cluded those reporting mean and SD (where availa-
ble) in meta- analysis; we used SD and N to estimate 
the SEM. To obtain an overall summary estimate of 
the prevalence across studies, we pooled the study- 
specific estimates using the inverse- variance– weighted 
method under a fixed- effects model. The fixed- effects 
(plural) model does not assume presence of the same 
underlying effect across the individual studies (unlike 
fixed [common] effect model) or exchangeability of ef-
fect (random- effects model).17– 19 To minimize the effect 
of studies with extremely small or extremely large prev-
alence estimates on the overall estimate, we stabilized 
the variance of the study- specific prevalence with the 
Freeman- Tukey single arcsine transformation before 
pooling the study- specific estimates.20 Between- study 
heterogeneity was assessed using the Cochran’s Q 
and I2 statistics.21 The I2 statistic estimates the per-
centage of total variation across studies attributable to 
true between- study differences rather than chance.22 
We took I2 value cutoffs of 25%, 50%, and 75% to 
represent low, medium, and high heterogeneity, re-
spectively. We explored sources of heterogeneity by 
performing meta- regression on study- level character-
istics that are known to affect CAC or coronary plaque 
burden, including average age of participants, percent-
age male participants, percentage Black participants, 
and average FRS. To account for difference between 
the HIV- positive and HIV- negative participants in terms 
of characteristics that influence CAC or coronary 
plaque burden, we predicted pooled values for CAC 
and coronary plaque burden adjusted to the mean 
FRS value across the studies in a meta- regression 
model. Additional heterogeneity analyses were per-
formed by subgrouping the studies on the basis of av-
erage values of several study- level variables that are 
known to affect CAC burden (listed above) into studies 
with less than the median value and those with greater 
than the median value for the respective variable. We 
assessed the presence of publication bias using a fun-
nel plot and the Egger test23 and by comparing the 
pooled prevalence between larger and smaller stud-
ies. We assessed the robustness of our results by per-
forming an influence analysis in which each individual 
study was omitted one at a time, and the effect on 
the pooled estimate was assessed. Methodological 
quality of included studies was assessed using the 
Newcastle- Ottawa Scale.24 This scale is calculated by 
assigning points to three aspects of study design, with 
a maximum total of 10 points: selection of study par-
ticipants (maximum 5 points), comparability of study 
groups (maximum 2 points), and ascertainment of the 
outcome of interest (maximum 3 points). The cut- offs 
of 0 to 3, 4 to 7, and 8 to 10 points were arbitrarily used 
to define high, moderate, and low risk of bias, respec-
tively. P<0.05 was considered statistically significant. 
We report pooled estimates and 95% CIs. All analy-
ses were performed using Stata software (version 15; 
StataCorp, College Station, TX). This study is reported 
according to Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses (PRISMA) guideline.25 
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review because it is a literature- based, aggregate data 
meta- analysis of already published studies and no di-
rect human subjects were involved.
Role of the Funding Source
The funding sources were not involved in the analy-
sis of data or preparation of this manuscript. The cor-
responding author had full access to all the data and 
had final responsibility for the decision to submit for 
publication.
RESULTS
The study selection process is shown in Figure S1. We 
identified 119 articles for full review on literature search, 
of which 43 articles were retained.4,9– 16,26– 59 Of the re-
tained articles, 22 represented multiple publications 
from 6 different studies,* yielding 27 unique studies in-
cluded in the meta- analyses (Table). The aforemen-
tioned 22 articles were retained because they provided 
complementary data to the information reported in the 
leading articles.
Basic Demographics
A total of 10 867 (6699 HIV- positive, 4168 HIV- negative) 
participants were included in the analyses. Table  S1 
provides comprehensive details on demographic char-
acteristics of the participants. The mean age of partici-
pants ranged from 23 to 60 years across the studies 
(weighted average, 52  years), the proportion of male 
participants ranged from 48% to 100% (weighted av-
erage, 86%), and the proportion of Black participants 
ranged from 7% to 100% (weighted average, 32%). The 
HIV- positive subgroup was younger (mean±SD age 
49±5 versus 57±5 years) and had a lower proportion of 
male participants (79% versus 96%), compared with the 
HIV- negative subgroup. There was higher prevalence of 
Black participants (37% versus 24%) in the HIV- positive 
versus HIV- negative subgroup. There were 15 studies 
that included both HIV- positive cases and HIV- negative 
controls allowing direct within study comparison. This 
subset of studies included a total of 6357 (2189 HIV- 
positive, 4168 HIV- negative) participants, with average 
age ranging from 23 to 60  years across the studies 
(weighted average, 55  years), the proportion of male 
participants ranged from 48% to 100% (weighted av-
erage, 93%), and the proportion of Black participants 
ranged from 7% to 46% (weighted average, 24%). The 
HIV- positive subgroup was younger (mean±SD age 
51±5 versus 57±5  years) and had a lower proportion 
of male participants (87% versus 96%) but had similar 
proportion of Black participants (23% versus 24%) com-
pared with the HIV- negative subgroup. The majority of 
studies (18/27) excluded subjects with prior coronary 
artery disease or percutaneous coronary intervention.
Clinical Characteristics
The weighted mean±SD of clinical characteristics of 
participants across the studies are detailed in Table S1. 
In brief, participants with diabetes mellitus comprised 
10±4% (HIV positive, 9±4%; HIV negative, 13±3%) 
across the studies. Participants with hypertension 
comprised 32±13% (HIV positive, 30±13%; HIV nega-
tive, 43±15%). Mean systolic blood pressure across 
the studies was 123±5 mm Hg for HIV- positive partici-
pants, compared with 125±3 mm Hg for HIV- negative 
participants. Smokers comprised 36±20% (HIV posi-
tive, 45±18%; HIV negative, 20±14%). The mean FRS 
for HIV- positive participants was 6±3 compared with 
18±5 (P<0.001) for HIV- negative participants. The 
percentage of HIV- positive participants on ART was 
91±12%. Mean duration of ART and mean CD4 count 
were 6±5 years and 543±89 cells/µL, respectively.
The clinical characteristics were similar when re-
stricting to the 15 studies with both HIV- positive par-
ticipants and HIV- negative controls. The HIV- positive 
participants had a higher prevalence of smoking 
(38±14%; HIV negative, 20±15%), and similar preva-
lence of diabetes mellitus (9±5% versus 13±3%) and 
hypertension (38±11% versus 43±13%), compared with 
HIV- negative participants. Eight of the studies that in-
cluded both HIV- positive and HIV- negative participants 
reported FRS scores, which yielded similar findings to 
the overall analyses (HIV positive, 9±3; HIV negative, 
18±5; P=0.002).
CAC Data
The details of CAC measurements, including average 
CAC score in patients with HIV, in the studies are pro-
vided in Table S2. The pooled estimate of percentage 
with presence of CAC (CAC >0), restricting to 12 stud-
ies with HIV- negative controls, was 45% (43%– 47%) 
for HIV- positive participants versus 52% (50%– 53%) 
for HIV- negative participants (Figure 1). The difference 
was not statistically significant after accounting for 
a difference in FRS between HIV- positive and HIV- 
negative participants (P=0.23). The predicted preva-
lence of CAC presence adjusting to FRS value of 8 (the 
average FRS across 7 studies reporting both FRS and 
CAC data) was 44% (34%– 53%) for HIV- positive par-
ticipants and 36% (25%– 46%) for HIV- negative par-
ticipants. The results were comparable when pooling 
all the studies with available information on presence 
of CAC (Figure S2). The combined estimate of the pro-
portion of patients with CAC score >100, restricting 
to studies that included HIV- negative controls, was 
18% (16%– 20%) for HIV- positive participants and 19% 
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There was significant heterogeneity across the stud-
ies for the outcomes assessed (P<0.001; I2>75%). The 
pooled percentage of CAC progression among HIV- 
positive individuals was 13% (11%– 16%) among stud-
ies that defined CAC progression as development of 
new CAC only, 13% (9%– 17%) among studies that de-
fined CAC progression as significant change in CAC 
values only, and 21% (18%– 24%) among studies that 
used a combination of both definitions (Figure  S4). 
The odds ratio of plaque progression comparing HIV- 
positive versus HIV- negative participants was 1.64 
(95% CI, 0.91– 2.37) for the 2 studies that made direct 
comparisons (Figure S5).
Coronary Plaque Data
All the studies reporting coronary plaque data included 
both HIV- positive participants and HIV- negative con-
trols, except for 1 study,41 which was excluded from 
these analyses. The pooled estimate across the stud-
ies for percentage of participants with presence of 
plaque on coronary CT angiogram was 64% (95% 
CI, 61%– 67%) versus 64% (95% CI, 60%– 67%) for 
the HIV- positive versus HIV- negative participants, re-
spectively, with significant heterogeneity across the 
studies (P<0.001; I2>75%; Figure  S6). The predicted 
prevalence for presence of coronary plaque adjusting 
to an FRS value of 9 (the average FRS across 6 stud-
ies reporting both FRS and coronary plaque data) was 
53% (95% CI, 48%– 57%) for HIV- positive participants 
and 48% (95% CI, 42%– 54%) for HIV- negative partici-
pants (P=0.13). The pooled prevalence of participants 
with calcified plaque was 31% (95% CI, 29%– 34%) for 
those with HIV and 41% (95% CI, 37%– 45%) for those 
without HIV (Figure 2A). By contrast, the correspond-
ing estimate for noncalcified plaque was 49% (95% 
CI, 47%– 52%) for those with HIV and 20% (95% CI, 
Figure 1. Meta- analysis of prevalence of coronary calcium >0 by HIV status*.
Black boxes represent the prevalence estimates and the horizontal bars about are for the 95% CIs. The blue diamond is for the 
pooled prevalence estimate and 95% CI. *Analyses restricted to studies that recruited both HIV+ cases and HIV− controls. CAC 
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17%– 23%) for those without HIV (Figure  2B). There 
was significant heterogeneity among the few studies 
in each subgroup. The pooled odds ratio for presence 
of plaque (HIV positive versus HIV negative) across 
3 studies was 1.09 (95% CI, 1.00– 1.17). The corre-
sponding pooled odds ratio estimates for presence of 
calcified and noncalcified plaque were 0.79 (95% CI, 
0.65– 0.92) and 1.23 (95% CI, 1.08– 1.38), respectively 
(Figure 3).
Heterogeneity Assessment
There was evidence of significant heterogeneity across 
the studies for most of the assessed outcomes, except 
for odds ratio estimate for noncalcified plaque (where 
the heterogeneity Q test was not statistically significant 
and I2 was <50%). Using meta- regression to assess the 
source of heterogeneity identified the average age of 
participants, average FRS, and proportion of male par-
ticipants were significantly associated with presence 
of CAC or coronary plaque (direct) across the stud-
ies. The proportion of Black participants was signifi-
cantly associated (inverse) with presence of CAC but 
not presence of coronary plaque. These identified vari-
ables explained between 23% and 81% of between- 
study variation in the meta- regression model (Figures 4 
and 5). We also assessed the proportion of participants 
with hypertension or participants who were smokers, 
and for HIV- positive participants only, proportion on 
ART and average CD4 count in relation to prevalence 
of CAC >0 in the studies in meta- regression analyses. 
Except for proportion of participants with hypertension, 
the other variables assessed were not significantly as-
sociated with presence of CAC across the studies 
(Figure S7). A substantial amount of heterogeneity still 
remained across the studies after accounting for these 
study- level characteristics. Additional analyses sub-
grouping the studies on the basis of average values of 
several variables that affect CAC (including age, per-
centage male, FRS, percentage with diabetes mellitus) 
into studies with less than the median value and those 
with greater than the median value were not able to 
account for further heterogeneity (Figures S8 and S9).
Study Quality and Risk of Bias 
Assessment
The Newcastle- Ottowa scoring system was used to 
assess the risk of bias among the articles included for 
analysis. The majority of the studies were of at least 
moderate quality (see Table and Table  S3), indicat-
ing mild to moderate risk for bias. Eyeballing of funnel 
plot and Egger test for bias did not suggest presence 
of significant publication bias (Figure  S10). Influence 
analyses did not indicate presence of undue effect on 
the pooled estimate for any single study (data available 
from authors).
DISCUSSION
In a meta- analysis of observational studies, which in-
cluded 6699 HIV positive and 4168 HIV from 27 unique 
studies reporting on the prevalence of CAC and coro-
nary plaque, we found similar combined prevalence of 
CAC and total coronary plaque between HIV- positive 
and HIV- negative participants, despite the younger 
age and overall lower traditional CVD risk factor burden 
among HIV participants. In addition, there was lower 
prevalence of calcified plaque and higher prevalence 
Figure 2. Meta- analysis of prevalence of calcified and non- calcified plaque prevalence by HIV status*.
Conventions as per Figure 1. *A, calcified plaque; B, non- calcified plaque. Analyses restricted to studies that recruited both HIV- 
positive cases and HIV- negative controls.
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of noncalcified plaque in those with HIV versus HIV- 
negative controls. Available data on CAC progression 
were not conclusive. There was substantial heteroge-
neity across the studies for most outcomes evaluated, 
which was partly explained by differences in study- 
level characteristics, including the average age of par-
ticipants, the proportion of male participants, the mean 
FRS, and the proportion of Black participants.
The lower FRS among those with HIV across the 
studies reflects the overall lower burden of traditional 
risk factor profile, including younger age and lower 
prevalence of hypertension; on the other hand, there 
were substantially more smokers and fewer men in 
the HIV group across the studies. Traditional risk 
factors appeared to contribute to subclinical CVD as 
demonstrated by the results of the meta- regression 
that showed a significant amount of the observed 
between- study heterogeneity was explained by 
some of these factors (eg, age, FRS). The compa-
rable CAC and total plaque prevalence between 
HIV- positive and HIV- negative participants, and the 
higher prevalence of noncalcified plaque despite a 
lower overall risk- factor profile in HIV participants, is 
consistent with prior reports about the role of non-
traditional risk factors, such as low- grade inflam-
mations associated with HIV infection and adverse 
effect of ART, that contribute to pathogenesis of CVD 
in PLHIV.2,60,61 The higher occurrence of noncalcified 
plaque in those with HIV may be partly attributable 
to the higher proportion of Black participants,62 who 
are known to have a higher risk burden of noncalci-
fied plaque, as well as higher inflammatory milieu in 
those with HIV.60 Smoking, which was more prevalent 
among those with HIV, may have likely contributed 
to the increased prevalence of all plaque types.63,64 
However, we did not find significant association be-
tween prevalence of smokers and CAC prevalence 
across the studies, which may be attributable to 
lack of accurate measurement of smoking (such as 
current versus former smoker and degree of smok-
ing), and also attributable to inherent limitation in the 
power of ecological association in meta- regression. 
Figure 3. Meta- analysis of odds ratio of plaque presence (HIV- positive vs HIV- negative) by type of plaque.
RR indicates relative risk. Red diamonds represent the effect estimates (odds ratios) and the horizontal bars about are for the 95% CIs. 
The size of the black boxes is proportional to the inverse variance. The black diamond is for the pooled odds ratio estimate and 95% 
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Similarly, we did not find significant association be-
tween ART percentage or average CD4 count and 
CAC prevalence in those with HIV. This may also 
reflect the limitations of ecological associations in 
meta- regression. It may also be attributable to the 
presumably opposite effects of high ART percent-
age and higher CD4 count on coronary artery dis-
ease, which may partly negate each other.57 Our 
findings are consistent with prior literature, includ-
ing an earlier, more limited review published in 2015, 
which found that participants with HIV have a higher 
prevalence of noncalcified plaques, which may be 
more prone to erosion and rupture.4– 6,10,29,32,33 In 
prior studies assessing actual cardiovascular events 
in patients with HIV compared with patients without 
HIV, there seems to be a consensus that patients 
with HIV are at increased risk of coronary events, in 
the range of 1.25- to 1.75- fold higher risk.65– 70 The 
higher prevalence of noncalcified plaque and possi-
bly earlier onset of CAC (as suggested by prior stud-
ies and this meta- analysis), may explain the higher 
risk of CVD observed in patients with HIV.70,71
Our findings have a number of important potential 
implications. Although the use of CAC as a risk as-
sessment tool for coronary events is well studied and 
validated,3 screening patients with HIV for the presence 
of CAC may not fully estimate their risk, as they are more 
likely to have noncalcified plaques6 that would not be 
included in CAC scores. Recent emerging data indicate 
that noncalcified plaques are more vulnerable to rup-
ture than harder, more calcified plaques and thus more 
likely to lead to myocardial infarction.72 Furthermore, 
screening for coronary artery disease using single 
CAC measurement may not be able to fully capture 
the risk profile in patients with HIV compared with pa-
tients without HIV. There has been prior research on 
the predictive value of CVD risk score in patients with 
HIV including FRS, Data Collection on Adverse Effects 
of Anti- HIV Drugs, the American College of Cardiology/
American Heart Association pooled cohort equations, 
Systematic Coronary Risk Evaluation high- risk equa-
tion, and Systematic Coronary Risk Evaluation for the 
Netherlands. Studies comparing these scores, which 
do not incorporate CAC imaging data, have reported 
conflicting levels of agreement.73– 77 However, most 
studies included in this systematic review did not re-
port on these risk score measures (aside from FRS); 
hence, these variables could not be included in sub-
group analysis and meta- regression. Future screening 
and imaging protocols and risk calculators that take 
Figure 4. Meta- regression of coronary calcium presence study estimates by various study- level characteristics.
The circles represent prevalence estimates for each study and the vertical bars represent 95% CIs. The red bars represent estimates 
for HIV- positive participants, and the green bar represents estimates for HIV- negative participants. The orange and green transverse 
lines were fitted using analytical weights of each estimate for HIV- positive and HIV- negative participants, respectively. R2 represents 
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the presence of CAC and nature of coronary plaque 
into account may have utility to fully capture this in-
creased risk profile in patients with HIV and may need 
to be considered starting at a younger age for individ-
uals with HIV.
There are several strengths to this review. First, 
the literature search was comprehensive, yielding 
the largest data set to date on CAC and coronary 
plaque in patients with HIV. Second, we used a rig-
orous process to identify multiple publications of the 
same study to avoid bias. Of 64 articles originally 
deemed eligible, 27 unique studies were retained 
after removing multiple publications. Third, we eval-
uated multiple subclinical measures of coronary ath-
erosclerosis, including mean CAC, presence of any 
CAC, high CAC burden (CAC >100), and longitudinal 
data for CAC progression, as well as various types 
of coronary plaque— all plaque, noncalcified plaque, 
and calcified plaque. Finally, we performed extensive 
subgroup analyses and sensitivity analyses as well 
as bias assessment, which suggested the robust-
ness of the findings.
The limitations of this meta- analysis merit consider-
ation. First, there was significant heterogeneity across 
the studies, leading to wider CIs of the pooled esti-
mates and limiting the generalizability of the findings. 
We performed heterogeneity analyses and identified 
factors that explained some of the between- study dif-
ferences. Second, the studies included were generally 
small in size, and nearly half of the studies did not have 
HIV- negative controls for comparison. Nonetheless, 
analyses restricting to studies with both HIV- positive 
and HIV- negative participants yielded comparable 
results. In addition, we collected detailed information 
on the characteristics of the HIV- positive and HIV- 
negative participants in each study— including age, 
sex composition, race, cardiovascular risk factors, 
and FRS— by pooling these factors for the HIV- positive 
and HIV- negative groups we have attempted to get 
a sense of the risk factor profile of the comparison 
groups. Third, data were particularly limited for pro-
gression of CAC and nature of plaque in patients with 
HIV, further reducing the power of the meta- analysis. 
Not all articles provided all of our desired measures 
of subclinical atherosclerosis, further limiting analyses. 
Fourth, statin usage is known to be associated with 
increased CAC scores78; however, studies reporting 
data on statin usage were too few to adjust for this 
variable in meta- regression. Fifth, the current study is 
a literature- based meta- analysis, and hence it was not 
possible to analyze individual data. Finally, while cur-
rent knowledge suggests that noncalcified plaques 
are more likely to rupture and cause heart attacks, 
having actual outcomes data to correlate this with the 
Figure 5. Meta- regression of plaque burden study estimates by various study- level characteristics.
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plaque data in prospective studies would strengthen 
the relevance of these findings. Further larger studies 
investigating progression and nature of atherosclero-
sis are needed.
CONCLUSIONS
In the present meta- analysis, we found that participants 
with HIV had a similar likelihood for having CAC and total 
coronary plaque as HIV- negative individuals, with higher 
prevalence of noncalcified plaque and lower burden of 
calcified plaque, despite their younger age and lower 
overall burden of traditional cardiovascular risk factors. 
Together, these data suggest that PLHIV have higher 
burden of noncalcified plaques and may develop sub-
clinical atherosclerosis at younger age. Data on CAC 
progression were more limited. This meta- analysis was 
limited by the availability of only few studies for the in-
dividual outcomes, significant heterogeneity across 
studies, aggregate nature of the data, and lack of as-
sessment of clinical CVD events. Thus, conclusions 
drawn must be interpreted in light of the limitations of 
the available data. Future large- scale longitudinal stud-
ies with HIV- negative controls, serial measurement of 
CAC score and coronary plaque are needed to further 
assess the characteristics of subclinical atherosclero-
sis in PLHIV. When possible, ascertainment of incident 
CVD events in relation to CAC and coronary plaque will 
help further elucidate the question.
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Table S1. Detailed demographics and baseline clinical characteristics for extracted studies; total and by HIV status. 











































Pereira B. 202050 CAC>0, CAC>100 739 739 0 92.8 92.8 - 84.2 84.2 - 7.5 7.5 - 56 56 - - - 
Krishnam M. 202039 CAC>0 143 143 0 83.2 83.2 - 72.7 72.7 - 7 7 - 46.4 46.4 - - - 
Chandra D. 201929 CAC>0; median CAC (Weston score) 234 177 57 82.1 76.3 100 - - - - - - 49.6 48.8 52.2   
Senoner T. 201953 
Mean CAC, Any plaque, Plaque 
Presence 138 69 69 71 73.9 68.1 - - - - - - 54 55 52 - - 
Tarr PE. 2018!,14,57 
Median CAC, CAC>0, CAC>100, CAC 
progression, Plaque Presence 704 428 276 83 86 79 89 91 88 7 7 6 54 52 56 9 10 
Korada SK 
2017@,4,10,38,46,47,52  
Median CAC, CAC >0, CAC >100, 
CAC Progression, Plaque Presence 976 602  100 100 100 58 - - 31 - - 54 - - - - 
Besutti G. 2016#,9,15, 16,28 
Mean CAC, Median CAC, CAC >0, 
CAC >100, OR CAC Progression, CAC 
Progression,  1446 1446 0 71 71 - - - - - - - 48 48 - 4 - 
Fitch, KV. 201636 
Median CAC, CAC>0, CAC>100, 
Plaque Presence 225 155 70 60 61 59 49 49 49 - - - 47 47 46 9 8 
Nadel, J. 201649 Median CAC 97 32 65 100 100 100 81 78 86 - - - 60 60 60 13 13 
Chow, D. 2015$,30,54 
Mean CAC, Median CAC, CAC>0, 
CAC >100, OR CAC 2833 100 2733 100 100 100 40 56 39 26 5 26 59 54 60 16 20 
Abd-Elmoniem, KZ. 
201426 Plaque Presence 46 35 11 48 54 27 37 34 45 46 49 36 23 22 25 - - 
Longenecker, CT. 201444 CAC>0 147 147 0 78 78 - - - - 69 69 - 46 46 - 3 - 
Baker, JV. 201413 CAC>0, CAC progression 436 436 0 78 78 - 59 59 - 27 27 - 42 42 - 5 - 
Kristoffersen US. 201340 Mean CAC, CAC >0, CAC >100 210 105 105 89 89 89 - - - - - - 47 47 47 9 8 
Lai S. 2013^,12,41-43 
Mean CAC, CAC >0, CAC 
progression, Plaque Presence 848 848 0 63 63 - 0 0 - 100 100 - 46 46 - 4 - 
Pereyra, F. 201351 
Median CAC, CAC>0, Plaque 
Presence 152 103 49 68 69 67 - - - - - - 49 49 48 10 9 
Hsue, PY. 201237 CAC >0, CAC >100 311 253 58 88 89 83 62 62 62 22 22 21 49 49 48 4 3 
Duarte, H. 201233 Mean CAC 52 26 26 85 85 85 48 42 54 40 54 27 53 53 52 12 10 
Fitch, K. 201235 Mean CAC 50 46 0 76 76 0 64 64 - 32 32 - 47 47 - - - 
d'Ettorre G. 201232 Mean CAC, CAC>100 55 55 0 86 86 - - - - - - - 48 48 - 4 - 
Subramanian S. 201255 Median CAC, CAC>0 54 27 27 93 93 93 - - - - - - 53 52 54 - - 
Falcone EL. 2011&,11,34,45,55 
Mean CAC, Median CAC, CAC >0, 
CAC >100, CAC Progression,  334 334 0 74 74 - 53 53 - 34 34 - 44 44 47 7 - 
Crum-Cianflone N. 201131 CAC>0, CAC>100 223 223 0 96 96 - 49 49 - 23 23 - 43 43 - - - 
Monteiro VS. 201148 CAC>0 53 53 0 51 51 - - - - - - - 43 43 - - - 
Vilela FD. 201158 Median CAC, CAC>0 40 40 0 53 53 - - - - - - - 46 46 - 4 - 
Acevedo M. 200227 Median CAC, CAC>0 85 17 68 - - - - - - - - - 46 46 46 10 - 
Talwani R. 200256 CAC>0 240 60 180 100 100 100 65 65 65 27 27 27 47 47 47 - - 


















































Pereira B. 202050 - 14 - - 633 5.8 5.8 - 21.4 21.4 - 42.9 42.9 - 130 - 
Yes 
Krishnam M. 202038 65 - - - - 16.1 16.1 - 13.3 13.3 - 32.2 32.2 - 122.9 - 
Yes 
Chandra D. 201929 87 - - - 602 4.7 2.8 7 - - - 43.2 24.9 100 126 132.1 
No 
Senoner T. 201953 - - - - 669 9 10 9 37 35 39 80 81 80 - - 
Yes 
Tarr PE. 2018!,,14,57 93 10.1 - 21 598 7 6 9 43 34 56 28 35 17 - - 
Yes 
Korada SK 
2017@,4,10,38,46,47,52  56 6.6 - 14 519 8 8 8 19 15 25 63 64 61 126 130 
No 
Besutti G. 2016#,,9,15,16,28 100 0.91 - - 571 13 13 - 38 38 - 39 39 - - - 
No 
Fitch, KV. 201636 99 - - - 552 9 10 7 22 24 16 43 44 40 119 117 
Yes 
Nadel, J. 201649 - 19 - 47 649 24 28 22 64 66 63 18 25 14 128 130 
No 
Chow, D. 2015$,,30,54 - - - - 498 14 9 14 - - - 16 24 16 126 125 
Yes 
Abd-Elmoniem, KZ. 
201426 71 15 14 - 502 - - - - - - - - - 123 116 
Yes 
Longenecker, CT. 201444 - 5.3 - - 613 - - - - - - 63 63 - 121 - 
Yes 
Baker, JV. 201413 78 2.8 - - 481 9 9 - - - - 41 41 - - - 
No 
Kristoffersen US. 201340 100 8.9 - - 636 - - - - - - 37 37 37 131 123 
Yes 
Lai S. 2013 ^,,12,41-43 - 3 - - 368 4 4 - 12 12 - 83 83 - 117 - 
Yes 
Pereyra, F. 201251 100 8.5 - - 571 9 12 4 23 26 16 40 40 41 121 117 
Yes 
Hsue, PY. 201257 68 5.7 14 - 471 5 6 2 27 28 21 62 62 - - - 
Yes 
Duarte, H. 201233 81 14 - - 582 25 35 15 60 65 54 31 31 31 126 135 
Yes 
Fitch, K. 201235 - - - - 583 - - - - - - - - - 121 - 
Yes 
d'Ettorre G. 201232 89 9.4 - - 493 - - - - - - - - - - - 
No 
Subramanian S. 201255 100 12.3 - - 641 - - - 17 19 15 15 22 7 124 121 
Yes 
Falcone EL. 2011 
&,,11,34,45,55 74 2.7 - - 454 - - - - - - 50 50 - 119 - 
No 
Crum-Cianflone N. 201131 83 6.4 - - 586 6 6 - 30 30 - 17 17 - - - 
No 
Monteiro VS. 201148 100 4.9 - - - 4 4 - 23 23 - 19 19 - - - 
Yes 
Vilela FD. 201158 100 - - - - 10 10 - 55 55 - 35 35 - 123 - 
Yes 
Acevedo M. 200227 100 3.1 - - 442 - 18 - - 47 - - 53 - - - 
Yes 
Talwani R. 200256 94 2.2 - - 483 - - - - - - - - - - - 
No 
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Table S2. CAC and Plaque Data among HIV(+) participants in the studies (% = percent of participants; CAC assess by non-contrast CT; plaque assess by CTA). 
Study 
Included HIV- 
Control? N HIV+ Mean CAC Median CAC % CAC > 0 
% CAC > 





Pereira B. 202050 No 739   53 18     
Krishnam M. 202039 No 143   29      
Chandra D. 201929 Yes 177   44      
Senoner T. 201953 Yes 69 149.4 ± 287.1     84  65 
Tarr PE. 2018 !,57 Yes 428  47 [14,183] 53 19  53 37 37 
Tarr PE. 2020 !,14 Yes 340     7 24 20 21 
Post WS. 2014@,52  Yes 450      78 35 63 
Kingsley LA. 2008@,4 Yes 615   47    56  
Kingsley LA. 2015 @,10  Yes 376  0 [0,24]   21    
Korada SK.  2017 @,38  Yes 602    22     
Zona S. 2012#,9 No 240  0 [0,11]   10    
Besutti G. 2016#,28 No 1446   35 10     
Guaraldi G. 2011#,15 No 876 40 ± 155        
Guaraldi G. 2012 #,16 No 132  0 [0-974]   34    
Fitch KV. 201636 Yes 155 23 ± 6 0 [0,9] 36 7  54 11 44 
Nadel J. 201649 Yes 32  56 [0,545]       
Chow D. 2015$,30 Yes 100 151.25 ± 390.06  58      
Shikuma CM. 2014 $,54 No 130  0 [0,47.66] 47 20     
Abd-Elmoniem, KZ. 201426 Yes 35      20  20 
Longenecker CT. 201444 No 147   37      
Baker JV. 201413 No 436     13    
Kristoffersen US. 201340 Yes 105 54.3 ± 16.7  37 11     
Lai S. 2009^,41  No 176      30   
Lai S. 2005 ^,43  Yes 124   36      
Lai S. 2013 ^,41  No 848   28      
Lai H. 2012 ^,12  No 119     12    
Pereyra  F. 201351 Yes 103  0 [0,16] 41   60   
Hsue PY. 201237 Yes 253   37 16     
Duarte H. 201233 Yes 26 114 ± 218        
Fitch K. 201235 No 46 48 ± 76        
d'Ettorre G. 201232 No 55 21.25 ± 63.53   11     
Subramanian S. 201255 Yes 27  0 [0,92.6] 37      
Volpe GE.  2013&,11  No 211  0.4 [0,5.2]   33    
Mangili A. 2007 &,45  No 314    8     
Falcone EL. 2010 &,34 No 298 46 ± 240.7        
Falcone EL. 2011 &,59 No 334   52      
Crum-Cianflone N. 201131 No 223   34 8     
Monteiro VS. 201148 No 53   21      
Vilela FD. 201158 No 40  0 33      
Acevedo M. 200227 Yes 17  14.4 [1,131.5] 76      
Talwani R. 200256 Yes 60   33      
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Table S3. Newcastle-Ottowa Scoring Table. 




Exp - 2 
Outcome / 
Exp - 3 Total Score 
Pereira B. 202050 1 0 1 1 0 1 1 0 0 5 
Krishnam M. 202039 0 0 1 1 0 1 1 0 0 4 
Chandra D. 201929 1 1 1 1 1 1 1 1 1 9 
Senoner T. 201953 1 1 1 1 1 1 1 0 0 7 
Tarr PE. 2018 ! ,14,57  1 1 1 1 1 1 1 1 1 9 
Korada SK. 2017 @,4,10,38,46,47,52 1 1 1 1 1 1 1 0 0 7 
Besutti G. 2016 #,9,15,16,28 1 0 1 1 0 1 1 0 0 5 
Fitch, KV. 201636 1 1 1 1 1 1 1 0 0 7 
Nadel, J. 201649 1 1 1 1 1 1 1 1 1 9 
Chow, D. 2015 $,,30,54 1 1 1 1 1 1 1 0 0 7 
Abd-Elmoniem, KZ. 201426 1 1 1 1 1 1 1 0 0 7 
Longenecker, CT. 201444 1 0 1 1 0 1 1 0 0 5 
Baker, JV. 201413 1 0 1 1 0 1 1 1 1 7 
Kristoffersen US. 201340 1 1 1 1 1 1 1 0 0 7 
Lai S. 2013 ^,12,41-43 1 0 1 1 0 1 1 0 0 5 
Pereyra, F. 201351 1 1 1 1 1 1 1 0 0 7 
Hsue, PY. 201237 1 1 1 1 1 1 1 0 0 7 
Duarte, H. 201233 1 1 1 1 1 1 1 0 0 7 
Fitch, K. 201235 1 0 1 1 0 1 1 1 1 7 
d'Ettorre G. 201232 1 0 1 1 0 1 1 0 0 5 
Subramanian S. 201255 1 1 1 1 1 1 1 0 0 7 
Falcone EL. 2011 &,11,34,45,55 1 0 1 1 0 1 1 0 0 5 
Crum-Cianflone N. 201131 1 0 1 1 0 1 1 0 0 5 
Monteiro VS. 201148 1 0 1 1 0 1 1 0 0 5 
Vilela FD. 201158 1 0 1 1 0 1 1 0 0 5 
Acevedo M. 200227 1 1 1 1 1 1 1 0 0 7 
Talwani R. 200256 1 1 1 1 1 1 1 0 0 7 
 
*Represents sub-total for N and weighted average for % (weighted by N) 
! - Tarr PE. 2018 contains the same study population as Tarr PE. 2020 
@ - Korada 2017 contains same study population as Post WS 2014, Monroe AK 2012, Metkus TS 2015, Kingsley 2015, Kingsley LA 2008 
# - Besutti G 2016 contains same study population as Guaraldi G 2011, Guaraldi G 2012,  Zona S 2012) 
$ - Chow C D 2015 contains same study population as Shikuma C 2014 
^ - Lai S 2013 contains same study population as Lai S 2009, Lai S 2005, Lai H 2012; (Dates of subject enrollment and analysis did not overlap for Lai 2005 and Lai 2013)   
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Figure S1. Study Selection Process.
1021 records identified through 
Embase database search
626 records identified through 
PubMed database search
1328 records after duplicates removed
(Screened using titles and abstracts)*
119 records retrieved for 
full-text review
42 records excluded
(same study or did not 
meet inclusion criteria)
77 of full-text articles 
selected for extraction
43 full-text articles 
representing 27 unique 
studies included in 
quantitative synthesis 
(meta-analysis)
34 full-text articles further 
excluded (duplicate data, 
insufficient data
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Figure S8. Subgroup analyses comparing HIV(+) vs. HIV(-) individuals, 
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Figure S9. Subgroup analyses comparing HIV(+) vs. HIV(-) individuals, 
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Table S1. Detailed demographics and baseline clinical characteristics for extracted studies; total and by HIV status. 











































Pereira B. 202050 CAC>0, CAC>100 739 739 0 92.8 92.8 - 84.2 84.2 - 7.5 7.5 - 56 56 - - - 
Krishnam M. 202039 CAC>0 143 143 0 83.2 83.2 - 72.7 72.7 - 7 7 - 46.4 46.4 - - - 
Chandra D. 201929 CAC>0; median CAC (Weston score) 234 177 57 82.1 76.3 100 - - - - - - 49.6 48.8 52.2   
Senoner T. 201953 
Mean CAC, Any plaque, Plaque 
Presence 138 69 69 71 73.9 68.1 - - - - - - 54 55 52 - - 
Tarr PE. 2018!,14,57 
Median CAC, CAC>0, CAC>100, CAC 
progression, Plaque Presence 704 428 276 83 86 79 89 91 88 7 7 6 54 52 56 9 10 
Korada SK 
2017@,4,10,38,46,47,52  
Median CAC, CAC >0, CAC >100, 
CAC Progression, Plaque Presence 976 602  100 100 100 58 - - 31 - - 54 - - - - 
Besutti G. 2016#,9,15, 16,28 
Mean CAC, Median CAC, CAC >0, 
CAC >100, OR CAC Progression, CAC 
Progression,  1446 1446 0 71 71 - - - - - - - 48 48 - 4 - 
Fitch, KV. 201636 
Median CAC, CAC>0, CAC>100, 
Plaque Presence 225 155 70 60 61 59 49 49 49 - - - 47 47 46 9 8 
Nadel, J. 201649 Median CAC 97 32 65 100 100 100 81 78 86 - - - 60 60 60 13 13 
Chow, D. 2015$,30,54 
Mean CAC, Median CAC, CAC>0, 
CAC >100, OR CAC 2833 100 2733 100 100 100 40 56 39 26 5 26 59 54 60 16 20 
Abd-Elmoniem, KZ. 
201426 Plaque Presence 46 35 11 48 54 27 37 34 45 46 49 36 23 22 25 - - 
Longenecker, CT. 201444 CAC>0 147 147 0 78 78 - - - - 69 69 - 46 46 - 3 - 
Baker, JV. 201413 CAC>0, CAC progression 436 436 0 78 78 - 59 59 - 27 27 - 42 42 - 5 - 
Kristoffersen US. 201340 Mean CAC, CAC >0, CAC >100 210 105 105 89 89 89 - - - - - - 47 47 47 9 8 
Lai S. 2013^,12,41-43 
Mean CAC, CAC >0, CAC 
progression, Plaque Presence 848 848 0 63 63 - 0 0 - 100 100 - 46 46 - 4 - 
Pereyra, F. 201351 
Median CAC, CAC>0, Plaque 
Presence 152 103 49 68 69 67 - - - - - - 49 49 48 10 9 
Hsue, PY. 201237 CAC >0, CAC >100 311 253 58 88 89 83 62 62 62 22 22 21 49 49 48 4 3 
Duarte, H. 201233 Mean CAC 52 26 26 85 85 85 48 42 54 40 54 27 53 53 52 12 10 
Fitch, K. 201235 Mean CAC 50 46 0 76 76 0 64 64 - 32 32 - 47 47 - - - 
d'Ettorre G. 201232 Mean CAC, CAC>100 55 55 0 86 86 - - - - - - - 48 48 - 4 - 
Subramanian S. 201255 Median CAC, CAC>0 54 27 27 93 93 93 - - - - - - 53 52 54 - - 
Falcone EL. 2011&,11,34,45,55 
Mean CAC, Median CAC, CAC >0, 
CAC >100, CAC Progression,  334 334 0 74 74 - 53 53 - 34 34 - 44 44 47 7 - 
Crum-Cianflone N. 201131 CAC>0, CAC>100 223 223 0 96 96 - 49 49 - 23 23 - 43 43 - - - 
Monteiro VS. 201148 CAC>0 53 53 0 51 51 - - - - - - - 43 43 - - - 
Vilela FD. 201158 Median CAC, CAC>0 40 40 0 53 53 - - - - - - - 46 46 - 4 - 
Acevedo M. 200227 Median CAC, CAC>0 85 17 68 - - - - - - - - - 46 46 46 10 - 
Talwani R. 200256 CAC>0 240 60 180 100 100 100 65 65 65 27 27 27 47 47 47 - - 


















































Pereira B. 202050 - 14 - - 633 5.8 5.8 - 21.4 21.4 - 42.9 42.9 - 130 - 
Yes 
Krishnam M. 202038 65 - - - - 16.1 16.1 - 13.3 13.3 - 32.2 32.2 - 122.9 - 
Yes 
Chandra D. 201929 87 - - - 602 4.7 2.8 7 - - - 43.2 24.9 100 126 132.1 
No 
Senoner T. 201953 - - - - 669 9 10 9 37 35 39 80 81 80 - - 
Yes 
Tarr PE. 2018!,,14,57 93 10.1 - 21 598 7 6 9 43 34 56 28 35 17 - - 
Yes 
Korada SK 
2017@,4,10,38,46,47,52  56 6.6 - 14 519 8 8 8 19 15 25 63 64 61 126 130 
No 
Besutti G. 2016#,,9,15,16,28 100 0.91 - - 571 13 13 - 38 38 - 39 39 - - - 
No 
Fitch, KV. 201636 99 - - - 552 9 10 7 22 24 16 43 44 40 119 117 
Yes 
Nadel, J. 201649 - 19 - 47 649 24 28 22 64 66 63 18 25 14 128 130 
No 
Chow, D. 2015$,,30,54 - - - - 498 14 9 14 - - - 16 24 16 126 125 
Yes 
Abd-Elmoniem, KZ. 
201426 71 15 14 - 502 - - - - - - - - - 123 116 
Yes 
Longenecker, CT. 201444 - 5.3 - - 613 - - - - - - 63 63 - 121 - 
Yes 
Baker, JV. 201413 78 2.8 - - 481 9 9 - - - - 41 41 - - - 
No 
Kristoffersen US. 201340 100 8.9 - - 636 - - - - - - 37 37 37 131 123 
Yes 
Lai S. 2013 ^,,12,41-43 - 3 - - 368 4 4 - 12 12 - 83 83 - 117 - 
Yes 
Pereyra, F. 201251 100 8.5 - - 571 9 12 4 23 26 16 40 40 41 121 117 
Yes 
Hsue, PY. 201257 68 5.7 14 - 471 5 6 2 27 28 21 62 62 - - - 
Yes 
Duarte, H. 201233 81 14 - - 582 25 35 15 60 65 54 31 31 31 126 135 
Yes 
Fitch, K. 201235 - - - - 583 - - - - - - - - - 121 - 
Yes 
d'Ettorre G. 201232 89 9.4 - - 493 - - - - - - - - - - - 
No 
Subramanian S. 201255 100 12.3 - - 641 - - - 17 19 15 15 22 7 124 121 
Yes 
Falcone EL. 2011 
&,,11,34,45,55 74 2.7 - - 454 - - - - - - 50 50 - 119 - 
No 
Crum-Cianflone N. 201131 83 6.4 - - 586 6 6 - 30 30 - 17 17 - - - 
No 
Monteiro VS. 201148 100 4.9 - - - 4 4 - 23 23 - 19 19 - - - 
Yes 
Vilela FD. 201158 100 - - - - 10 10 - 55 55 - 35 35 - 123 - 
Yes 
Acevedo M. 200227 100 3.1 - - 442 - 18 - - 47 - - 53 - - - 
Yes 
Talwani R. 200256 94 2.2 - - 483 - - - - - - - - - - - 
No 
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Table S2. CAC and Plaque Data among HIV(+) participants in the studies (% = percent of participants; CAC assess by non-contrast CT; plaque assess by CTA). 
Study 
Included HIV- 
Control? N HIV+ Mean CAC Median CAC % CAC > 0 
% CAC > 





Pereira B. 202050 No 739   53 18     
Krishnam M. 202039 No 143   29      
Chandra D. 201929 Yes 177   44      
Senoner T. 201953 Yes 69 149.4 ± 287.1     84  65 
Tarr PE. 2018 !,57 Yes 428  47 [14,183] 53 19  53 37 37 
Tarr PE. 2020 !,14 Yes 340     7 24 20 21 
Post WS. 2014@,52  Yes 450      78 35 63 
Kingsley LA. 2008@,4 Yes 615   47    56  
Kingsley LA. 2015 @,10  Yes 376  0 [0,24]   21    
Korada SK.  2017 @,38  Yes 602    22     
Zona S. 2012#,9 No 240  0 [0,11]   10    
Besutti G. 2016#,28 No 1446   35 10     
Guaraldi G. 2011#,15 No 876 40 ± 155        
Guaraldi G. 2012 #,16 No 132  0 [0-974]   34    
Fitch KV. 201636 Yes 155 23 ± 6 0 [0,9] 36 7  54 11 44 
Nadel J. 201649 Yes 32  56 [0,545]       
Chow D. 2015$,30 Yes 100 151.25 ± 390.06  58      
Shikuma CM. 2014 $,54 No 130  0 [0,47.66] 47 20     
Abd-Elmoniem, KZ. 201426 Yes 35      20  20 
Longenecker CT. 201444 No 147   37      
Baker JV. 201413 No 436     13    
Kristoffersen US. 201340 Yes 105 54.3 ± 16.7  37 11     
Lai S. 2009^,41  No 176      30   
Lai S. 2005 ^,43  Yes 124   36      
Lai S. 2013 ^,41  No 848   28      
Lai H. 2012 ^,12  No 119     12    
Pereyra  F. 201351 Yes 103  0 [0,16] 41   60   
Hsue PY. 201237 Yes 253   37 16     
Duarte H. 201233 Yes 26 114 ± 218        
Fitch K. 201235 No 46 48 ± 76        
d'Ettorre G. 201232 No 55 21.25 ± 63.53   11     
Subramanian S. 201255 Yes 27  0 [0,92.6] 37      
Volpe GE.  2013&,11  No 211  0.4 [0,5.2]   33    
Mangili A. 2007 &,45  No 314    8     
Falcone EL. 2010 &,34 No 298 46 ± 240.7        
Falcone EL. 2011 &,59 No 334   52      
Crum-Cianflone N. 201131 No 223   34 8     
Monteiro VS. 201148 No 53   21      
Vilela FD. 201158 No 40  0 33      
Acevedo M. 200227 Yes 17  14.4 [1,131.5] 76      
Talwani R. 200256 Yes 60   33      
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Table S3. Newcastle-Ottowa Scoring Table. 




Exp - 2 
Outcome / 
Exp - 3 Total Score 
Pereira B. 202050 1 0 1 1 0 1 1 0 0 5 
Krishnam M. 202039 0 0 1 1 0 1 1 0 0 4 
Chandra D. 201929 1 1 1 1 1 1 1 1 1 9 
Senoner T. 201953 1 1 1 1 1 1 1 0 0 7 
Tarr PE. 2018 ! ,14,57  1 1 1 1 1 1 1 1 1 9 
Korada SK. 2017 @,4,10,38,46,47,52 1 1 1 1 1 1 1 0 0 7 
Besutti G. 2016 #,9,15,16,28 1 0 1 1 0 1 1 0 0 5 
Fitch, KV. 201636 1 1 1 1 1 1 1 0 0 7 
Nadel, J. 201649 1 1 1 1 1 1 1 1 1 9 
Chow, D. 2015 $,,30,54 1 1 1 1 1 1 1 0 0 7 
Abd-Elmoniem, KZ. 201426 1 1 1 1 1 1 1 0 0 7 
Longenecker, CT. 201444 1 0 1 1 0 1 1 0 0 5 
Baker, JV. 201413 1 0 1 1 0 1 1 1 1 7 
Kristoffersen US. 201340 1 1 1 1 1 1 1 0 0 7 
Lai S. 2013 ^,12,41-43 1 0 1 1 0 1 1 0 0 5 
Pereyra, F. 201351 1 1 1 1 1 1 1 0 0 7 
Hsue, PY. 201237 1 1 1 1 1 1 1 0 0 7 
Duarte, H. 201233 1 1 1 1 1 1 1 0 0 7 
Fitch, K. 201235 1 0 1 1 0 1 1 1 1 7 
d'Ettorre G. 201232 1 0 1 1 0 1 1 0 0 5 
Subramanian S. 201255 1 1 1 1 1 1 1 0 0 7 
Falcone EL. 2011 &,11,34,45,55 1 0 1 1 0 1 1 0 0 5 
Crum-Cianflone N. 201131 1 0 1 1 0 1 1 0 0 5 
Monteiro VS. 201148 1 0 1 1 0 1 1 0 0 5 
Vilela FD. 201158 1 0 1 1 0 1 1 0 0 5 
Acevedo M. 200227 1 1 1 1 1 1 1 0 0 7 
Talwani R. 200256 1 1 1 1 1 1 1 0 0 7 
 
*Represents sub-total for N and weighted average for % (weighted by N) 
! - Tarr PE. 2018 contains the same study population as Tarr PE. 2020 
@ - Korada 2017 contains same study population as Post WS 2014, Monroe AK 2012, Metkus TS 2015, Kingsley 2015, Kingsley LA 2008 
# - Besutti G 2016 contains same study population as Guaraldi G 2011, Guaraldi G 2012,  Zona S 2012) 
$ - Chow C D 2015 contains same study population as Shikuma C 2014 
^ - Lai S 2013 contains same study population as Lai S 2009, Lai S 2005, Lai H 2012; (Dates of subject enrollment and analysis did not overlap for Lai 2005 and Lai 2013)   
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Figure S1. Study Selection Process.
1021 records identified through 
Embase database search
626 records identified through 
PubMed database search
1328 records after duplicates removed
(Screened using titles and abstracts)*
119 records retrieved for 
full-text review
42 records excluded
(same study or did not 
meet inclusion criteria)
77 of full-text articles 
selected for extraction
43 full-text articles 
representing 27 unique 
studies included in 
quantitative synthesis 
(meta-analysis)
34 full-text articles further 
excluded (duplicate data, 
insufficient data
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Figure S8. Subgroup analyses comparing HIV(+) vs. HIV(-) individuals, 
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Figure S9. Subgroup analyses comparing HIV(+) vs. HIV(-) individuals, 
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